Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Feb 04, 2021 11:32am
91 Views
Post# 32470483

RE:RE:RE:Today’s trading

RE:RE:RE:Today’s tradingI gotta say, Luc is looking smarter by the day. And I doubt he would have done that deal, at least on those atrocious terms.

jfm1330 wrote: Yes, his name is Paul Pommier and he is by far the biggest shareholder on the BOD and management of Thera and he bought some more in the last offering. Oh! And by the way, he is a good friend of Luc Tanguay. You know the guy who had the foresshight to buy Katana for a few millions two years ago...


Wino115 wrote: Interesting. Don't forget one of the Board members is also a past NBF guy.  Guess they didn't convince them enough.  This is where capitalizing on the news via a bit of PR would be helpful.  Wonder if they understand that in the CFO office?  Get going Dubuc...make up for  your lack of contacts in finance by getting some PR on your side.

jeffm34 wrote: I see Dubuc's friends over at NBF are by far the biggest sellers so far this morning. So much for their claim the new investors are in it for the long term. 

 




<< Previous
Bullboard Posts
Next >>